| abstract |
The N-acylamino compounds of formula (VI) are as defined in the claims which are inhibitors of the converting enzyme interleukin-1beta, a process for their preparation, and pharmaceutical compositions containing them. These ICE inhibitors are characterized by specific structural and physical-chemical features. In particular, said compounds and pharmaceutical compositions are particularly well suited for inhibiting ICE activity and, as a result, can be advantageously used as agents for IL-1 mediated diseases, apoptosis, IGIFα IFN-γ, inflammatory diseases, autoimmune diseases, bone disruption diseases, proliferative disorders, contagious diseases, degenerative diseases and necrotic diseases. |